PMID- 17628388
OWN - NLM
STAT- MEDLINE
DCOM- 20080225
LR  - 20161209
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 36
IP  - 12 Pt 2
DP  - 2007 Dec
TI  - [Strategies to reverse fibrotic lesions of the kidney].
PG  - 1857-64
AB  - The deterioration of renal function in chronic kidney disease is related to the 
      progression of renal fibrosis, which was long considered unavoidable. Today, the 
      reversibility of renal fibrotic lesions is a reality, although still clinically 
      rare. Because angiotensin II is highly profibrotic, blocking its action 
      effectively protects the kidney, as numerous clinical trials have shown. The 
      development of interstitial fibrosis is secondary to the 
      epithelial-to-mesenchymal transition induced by transforming growth factor 
      (TGF)-beta. Bone morphogenic protein-7 (BMP-7) and hepatocyte growth factor (HGF) 
      induce the reverse transition and thus open up perspectives for treatment. 
      Degradation of the extracellular matrix by matrix metalloproteinases or other 
      enzymes is another therapeutic pathway. Renal regeneration may be promoted by 
      modulation of hypoxia-inducible factor-1 (HIF-1) and vascular endothelial growth 
      factor (VEGF).
FAU - Boffa, Jean-Jacques
AU  - Boffa JJ
AD  - Service nephrologie et dialyses, Hopital Tenon, AP-HP, Paris. 
      jean-jacques.boffa@tnn.aphp.fr
FAU - Ronco, Pierre
AU  - Ronco P
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Strategies pour faire regresser les lesions de fibrose renale.
DEP - 20070712
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Bone Morphogenetic Proteins)
RN  - 0 (Transforming Growth Factor beta)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
SB  - IM
MH  - Angiotensin II Type 1 Receptor Blockers/therapeutic use
MH  - Bone Morphogenetic Proteins/physiology
MH  - Disease Progression
MH  - Epithelial Cells/cytology
MH  - Extracellular Matrix/metabolism
MH  - Fibrosis/metabolism/*therapy
MH  - Hepatocyte Growth Factor/physiology
MH  - Humans
MH  - Kidney/*pathology/physiology
MH  - Mesoderm/cytology
MH  - Regeneration
MH  - Transforming Growth Factor beta/metabolism
RF  - 55
EDAT- 2007/07/14 09:00
MHDA- 2008/02/26 09:00
CRDT- 2007/07/14 09:00
PHST- 2007/04/24 00:00 [received]
PHST- 2007/04/26 00:00 [accepted]
PHST- 2007/07/14 09:00 [pubmed]
PHST- 2008/02/26 09:00 [medline]
PHST- 2007/07/14 09:00 [entrez]
AID - S0755-4982(07)00479-4 [pii]
AID - 10.1016/j.lpm.2007.04.033 [doi]
PST - ppublish
SO  - Presse Med. 2007 Dec;36(12 Pt 2):1857-64. doi: 10.1016/j.lpm.2007.04.033. Epub 
      2007 Jul 12.